New hypertension drug shows promise in early trial
NCT ID NCT00562549
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called SLx-2101 in 26 adults with moderate to severe high blood pressure. Participants took the pill once daily for up to 12 days to see how well it lowers blood pressure and if it is safe. The goal is to find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SLx-2101
What this could lead to
If it works, this could point toward a new daily pill to help control high blood pressure.
What could go wrong
This is a small, early-phase trial with only 26 people and short treatment duration. The drug may not lower blood pressure enough or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, CB2 2QQ, United Kingdom